Author:
Braess Jan, ,Amler Susanne,Kreuzer Karl-Anton,Spiekermann Karsten,Lindemann Hans Walter,Lengfelder Eva,Graeven Ullrich,Staib Peter,Ludwig Wolf-Dieter,Biersack Harald,Ko Yon-Dschun,Uppenkamp Michael J.,De Wit Maike,Korsten Stefan,Peceny Rudolf,Gaska Tobias,Schiel Xaver,Behringer Dirk M.,Kiehl Michael G.,Zinngrebe Bettina,Meckenstock Gerald,Roemer Eva,Medgenberg Dirk,Spaeth-Schwalbe Ernst,Massenkeil Gero,Hindahl Heidrun,Schwerdtfeger Rainer,Trenn Guido,Sauerland Cristina,Koch Raphael,Lablans Martin,Faldum Andreas,Görlich Dennis,Bohlander Stefan K.,Schneider Stephanie,Dufour Annika,Buske Christian,Fiegl Michael,Subklewe Marion,Braess Birgit,Unterhalt Michael,Baumgartner Anja,Wörmann Bernhard,Beelen Dietrich,Hiddemann Wolfgang
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference19 articles.
1. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.
2. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–64.
3. Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Gorlich D, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128:686–98.
4. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.
5. Buchner T, Hiddemann W, Wormann B, Loffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93:4116–24.